Piper Sandler lowered the firm’s price target on Envista to $16 from $18 and keeps a Neutral rating on the shares. The firm is updating its model and cutting its margin plus EPS expectations for the next several quarters. With new CEO Paul Keel having now been in the seat for a few months and with dental trends stable at best, Piper is of the opinion that a more comprehensive expectation reset could be in the cards.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST: